These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1697448)

  • 41. The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
    Gallus A; Murphy W; Nacey J; Morris M; Sutherland P; Marshall V; Magnani H
    Thromb Res; 1989 Oct; 56(2):229-38. PubMed ID: 2482549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis.
    Von Bonsdorff M; Stiekema J; Harjanne A; Alapiessa U
    Int J Artif Organs; 1990 Feb; 13(2):103-8. PubMed ID: 2347652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haemofiltration/haemodialysis in patients with heparin-associated thrombocytopenia.
    Chong BH; Jacques T
    Intensive Care Med; 1991; 17(7):437. PubMed ID: 1774405
    [No Abstract]   [Full Text] [Related]  

  • 44. Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.
    Stiekema JC; de Boer A; Danhof M; Kroon C; Broekmans AW; van Dinther TG; Voerman J; Breimer DD
    Haemostasis; 1990; 20(3):136-46. PubMed ID: 1696921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
    De Boer A; Stiekema JC; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of deep vein thrombosis following total hip replacement surgery by Orgaran. Summary.
    ten Cate JW
    Haemostasis; 1992; 22(2):109-11. PubMed ID: 1379964
    [No Abstract]   [Full Text] [Related]  

  • 47. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delayed thrombin generation is not associated with fibrinopeptide formation during prolonged cardiopulmonary bypass with hirudin anticoagulation.
    Belway D; Rubens FD; Henley B; Babaev A; Mesana T
    Perfusion; 2006 Dec; 21(5):259-62. PubMed ID: 17201079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.
    Dryjski M; Mikat E; Bjornsson TD
    J Vasc Surg; 1988 Nov; 8(5):623-33. PubMed ID: 2460647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice.
    Brister SJ; Ofosu FA; Heigenhauser GJ; Gianese F; Buchanan MR
    Thromb Haemost; 1994 Apr; 71(4):468-73. PubMed ID: 8052965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
    Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
    Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiopulmonary bypass using lomoparan: monitoring of anticoagulation using anti-Xa levels and thromboelastography.
    Sharma S; Newman M; Gibbs N; Parkinson G
    Aust N Z J Surg; 1997 Jun; 67(6):392-4. PubMed ID: 9193279
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
    Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H
    Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity.
    ten Cate H; Lamping RJ; Henny CP; Prins A; ten Cate JW
    Clin Chem; 1984 Jun; 30(6):860-4. PubMed ID: 6723041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.
    de Boer A; Danhof M; Cohen AF; Magnani HN; Breimer DD
    Thromb Haemost; 1991 Aug; 66(2):202-7. PubMed ID: 1722918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
    Magnani HN; Ruys AH
    J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):254-5. PubMed ID: 8126524
    [No Abstract]   [Full Text] [Related]  

  • 58. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Breimer DD
    J Clin Pharmacol; 1991 Jul; 31(7):611-7. PubMed ID: 1716644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172.
    Chong BH; Ismail F; Cade J; Gallus AS; Gordon S; Chesterman CN
    Blood; 1989 May; 73(6):1592-6. PubMed ID: 2713496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.